Request a Callback
  • Home
  • Solutions
  • Technology
  • Products
  • Resources

      Resources

      Publication

      Peer-reviewed research and manuscripts

      Whitepapers & Reports

      In-depth technical analyses

      Guide & Explainers

      Educational content for all audiences

      FAQs

      Answers to common questions

      Case Studies

      Real-world clinical impact stories

      Expert Insights

      Articles and webinars from our team

      Newsletters

      Latest developments delivered to you

      Blogs

      Latest developments delivered to you

      We’ve just launched a new product!

      Integrated NGS + IHC with WHO-aligned treatment guidance in 10–12 days. 

      Explore Oncolndx® 360° Endometrium
  • Press & News

      Press & News

      Press Releases

      Official announcements and statements

      In the News

      Media coverage and mentions

      Company Updates

      Latest news and developments

      Events & Conferences

      Events, talks, and participation

      Coming Soon

  • About Us

      About Us

      Our Mission 

      Why we do, what we do

      Our Team 

      Leadership, advisors, and board

      Our Lab 

      Certifications and capabilities

      Careers 

      Join our team

      We’re hiring!

      Media & Recognition 

      Awards and press coverage

  • Home
  • Solutions
  • Technology
  • Products
  • Resources

      Resources

      Publication

      Peer-reviewed research and manuscripts

      Whitepapers & Reports

      In-depth technical analyses

      Guide & Explainers

      Educational content for all audiences

      FAQs

      Answers to common questions

      Case Studies

      Real-world clinical impact stories

      Expert Insights

      Articles and webinars from our team

      Newsletters

      Latest developments delivered to you

      Blogs

      Latest developments delivered to you

      We’ve just launched a new product!

      Integrated NGS + IHC with WHO-aligned treatment guidance in 10–12 days. 

      Explore Oncolndx® 360° Endometrium
  • Press & News

      Press & News

      Press Releases

      Official announcements and statements

      In the News

      Media coverage and mentions

      Company Updates

      Latest news and developments

      Events & Conferences

      Events, talks, and participation

      Coming Soon

  • About Us

      About Us

      Our Mission 

      Why we do, what we do

      Our Team 

      Leadership, advisors, and board

      Our Lab 

      Certifications and capabilities

      Careers 

      Join our team

      We’re hiring!

      Media & Recognition 

      Awards and press coverage

x

    Request a Callback

    Fill in your details and our team will get in touch with you.


    Advancing Single-Cell Precision

    • Featured
    • Publications

    Analytical Validation and Clinical Implementation of a 1080-Gene Comprehensive Genomic Profiling Assay with Integrated Cloud-Based Analysis for Solid Tumor Molecular Oncology 

    The Problem With Small Panels  Precision oncology depends on knowing the full genomic landscape of a patient’s tumour. Yet most clinical laboratories continue to rely on gene panels covering only 50 to 100 genes– panels that routinely miss critical hotspots, emerging driver mutations, and pan-tumour...
    • 3 mins read
    Read Article
    • Featured
    • Publications

    Potential of urine liquid biopsy in detecting of clinically relevant genomic alterations in advanced genitourinary cancers. 

    When Plasma Can’t Find It; Urine Can Plasma-based liquid biopsy has transformed how we detect and monitor cancer genomically. But it has a quiet blind spot: in patients with low circulating tumour DNA burden, clonal evolution, or treatment-related suppression of ctDNA shedding, plasma...
    • 2 mins read
    Read Article
    • Featured
    • Publications

    Single-Cell Circulating Tumor Cell Genomics Reveals KRAS-Independent Oncogenic Sub-Populations and Longitudinal Clonal Evolution in Metastatic Pancreatic Adenocarcinoma 

      Pancreatic Cancer’s Moving Target:-  Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal cancers and one of the hardest to treat precisely, because it doesn’t stay still. PDAC tumours exhibit profound intratumoral heterogeneity, with multiple genetically distinct cell populations evolving rapidly under treatment pressure. Conventional tissue...
    • 4 mins read
    Read Article

    Filters

    Content Type

    Cancer Type

    Test Type

    Use Case

    Biomarkers/Mutations

    Loading...
    Close
    1Cell.Ai
    Powered by  GDPR Cookie Compliance
    Privacy Overview

    This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.